ARS Pharmaceuticals, Inc.
SPRY
$14.88
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 89.15M | 2.57M | 500.00K | 10.00K | 30.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 89.15M | 2.57M | 500.00K | 10.00K | 30.00K |
| Cost of Revenue | 20.36M | 19.87M | 18.34M | 18.75M | 20.07M |
| Gross Profit | 68.79M | -17.30M | -17.84M | -18.74M | -20.04M |
| SG&A Expenses | 71.88M | 43.21M | 38.90M | 43.26M | 47.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.23M | 63.07M | 57.24M | 62.01M | 67.55M |
| Operating Income | -3.08M | -60.51M | -56.74M | -62.00M | -67.52M |
| Income Before Tax | 8.29M | -49.10M | -44.84M | -49.70M | -54.37M |
| Income Tax Expenses | 288.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.00 | -49.10 | -44.84 | -49.70 | -54.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.00M | -49.10M | -44.84M | -49.70M | -54.37M |
| EBIT | -3.08M | -60.51M | -56.74M | -62.00M | -67.52M |
| EBITDA | -3.00M | -60.44M | -56.67M | -61.94M | -67.45M |
| EPS Basic | 0.08 | -0.51 | -0.47 | -0.52 | -0.57 |
| Normalized Basic EPS | 0.04 | -0.33 | -0.30 | -0.34 | -0.37 |
| EPS Diluted | -0.01 | -0.51 | -0.47 | -0.52 | -0.57 |
| Normalized Diluted EPS | -0.02 | -0.33 | -0.30 | -0.34 | -0.37 |
| Average Basic Shares Outstanding | 387.74M | 386.48M | 385.02M | 383.11M | 380.85M |
| Average Diluted Shares Outstanding | 409.56M | 386.48M | 385.02M | 383.11M | 380.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |